Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

BMC Psychiatry

Volumn 5, Issue , 2005, Pages

  Faries, Douglas E ^a   Ascher Svanum, Haya ^a   Zhu, Baojin ^a   Correll, Christoph U ^b   Kane, John ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ARTICLE; CALCULATION; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NONPARAMETRIC TEST; POLYPHARMACY; PRACTICE GUIDELINE; SCHIZOPHRENIA; STATISTICAL MODEL; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; LONGITUDINAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; POLYPHARMACY; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 26844433208     PISSN: 1471244X     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-5-26     Document Type: Article

References (36)

1. American Psychiatric Association: Practice Guidelines for the Treatment of Patients with Schizophrenia, Second Edition. Am J Psychiatry 2004, 161:1-56.
2. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004, 30:193-217.
3. National Institute for Clinical Excellence: Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance 2002, London.
4. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP: The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999, 60: 649-657.
5. The expert consensus guideline series: Treatment of schizophrenia.. J Clin Psychiatry 1999, Suppl 11:3-80.
6. Weiden PJ, Casey DE: "Polypharmacy": Combining antipsychotic medications in the treatment of schizophrenia. J Prac Psych and Behav Hlth 1999, 7:229-233.
7. Miller AL, Craig CS: Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002, 28:105-109.
8. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC: Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, 1998-2000. J Clin Psychiatry 2004, 65:1377-1388.
9. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N: Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003, 54:55-59.
10. Loosbrock DL, Zhao Z: Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. Journal of Mental Health Policy Economics 2003, 6: 67-75.
11. Schumacher JE, Makela EH, Griffin HR: Multiple antipsychotic medication prescribing patterns. Annals of Pharmacotherapy 2003, 37: 951-955.
12. McCue, R.E., Waheed R., Urcuyo L: Polypharmacy in patients with schizophrenia. Journal of Clinical Psychiatry 2003, 64: 984-989.
13. Stahl SM: Antipsychotic polypharmacy: Squandering precious resources? J Clin Psychiatry 2002, 63: 93-94.
14. Covell, NH, Jackson CT, Evans AC, Essock SM: Antipsychotic prescribing practices in Connecticut's Public Mental Health System: Rates of changing medications and prescribing styles. Schizophr Bull 2002, 28:17-29.
15. Weissman EM: Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York Metropolitan Region. Schizoph Bull 2002, 28:31-42.
16. Centorrino F, Goren JL, Hennen J, Salavtore P, Kelleher JP, Baldessarini RJ: Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 2004, 161:700-706.
17. Clark RE, Bartels SJ, Mellman TA, Peacock WJ: Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002, 28: 75-84.
18. Jerrell JM: Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002, 28:589-605.
19. Procyshyn RM, Kennedy NB, Tse G, Thompson B: Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001, 46:334-339.
20. Yuzda MSK: Combination antipsychotics: what is the evidence? J Inform Pharamcother 2000, 2:300-305.
21. Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002, 106: 323-330.
22. Meltzer HY, Kostakoglu A: Combining antipsychotics: is there evidence for efficacy? Psychiatric Times 2000, 17: 25-32.
23. Chiles JA, Miller AL, Crismon LM, Rush AJ, Krasnoff AS, Shon SS: The Texas medication algorithm project: development and implementation of the schizophrenia algorithm. Psychiatr Serv 1999, 50: 69-74.
24. Koshino Y: Algorithm for treatment-refractory schizophrenia. Psychiatry Clin Neurosci 1999, 53: S9-S13.
25. Jaffe AB, Levine J: Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003, 12:41-48.
26. Advokat C, Dixon D, Schnedier J, Comaty JE: Comparison of risperidone and olanzapine as used under "real world" conditions in a state psychiatric hospital. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004, 28:484-495.
27. Correll CU, Kane JM, O'Shea D, Razi K, Malhotra AK: Antipsychotic polypharmacy inn the treatment of schizophrenia. Schizophr Res 2003, Suppl 1:37.
28. Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey J: The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value in Health 2004, 7:22-35.
29. Zhao Z, Tunis SL, Lage M: Medication treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest 2002, 22:741-749.
30. Wang PF, Zhao Z: Comparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophrenia. Value in Health 2003, 6:355.
31. Ascher-Svanum H, Zhu B, Faries D, Ernst FR: A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004, 3:11 Epub June 02, 2004
32. Swanson JW, Swartz MS, Elbogen EB: Effectiveness of Atypical Antipsychotic Medications in Reducing Violent Behavior Among Persons with Schizophrenia in Community-Based Treatment. Schizophr Bull 2004, 30:3-20.
33. Liang KY, Zeger SL: Longitudinal Data Analysis Using Generalized Linear Models. Biometrika 1986, 73:13-22.
34. Chernick MR: Bootstrap Methods: A Practicioner's Guide. John Wiley & Sons, Inc. New York, NY, 1999.
35. Davis J, Chen N: Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004, 24:192-208.
36. Rupnow M, Stahl S, Greenspan A, Kosik-Gonzalez C, Gharabawi G: Use and cost of polypharmacy in schizophrenia: Data from a randomized double-blind study of risperidone and quetiapine. Schizophr Bull, 2005; 31:550.